Longevity Health Holdings, Inc. (XAGE)
Longevity Health Holdings, Inc. (XAGE)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss from continuing operations | -1,431,713 | -2,083,222 | -1,429,755 | -3,392,305 |
| Loss from discontinued operations, net of tax | NaN | NaN | NaN | 0 |
| Stock-based compensation | 145,927 | 193,712 | 189,926 | 309,152 |
| Depreciation and amortization of intangible assets | 15,038 | 16,271 | 16,268 | 46,136 |
| Amortization of right of use assets | 22,282 | 21,826 | 21,379 | 93,174 |
| Loss on forward purchase agreement | NaN | NaN | NaN | 0 |
| Change in fair value of earnout liabilities | -96,053 | -93,110 | -86,104 | 29,630 |
| Inventory write-down | 196,684 | 13,881 | 47,082 | NaN |
| Accounts receivable | 12,165 | -10,022 | -7,974 | -26,155 |
| Inventory | -31,376 | -36,459 | -112,184 | -222,210 |
| Prepaid expenses | -101,532 | -129,168 | -87,421 | -321,096 |
| Income taxes receivable | NaN | -301,838 | NaN | NaN |
| Accounts payable | 551,354 | 323,824 | -455,757 | 258,791 |
| Accrued expenses and other liabilities | 15,112 | 845,599 | 77,816 | 592,530 |
| Amortization of debt discount | NaN | NaN | NaN | 0 |
| Lease liability | -24,665 | -22,635 | -22,190 | -95,712 |
| Net cash used in operating activities | -485,291 | -306,367 | -1,433,756 | -1,589,143 |
| Cash paid for offering costs | NaN | NaN | NaN | 15,000 |
| Cash paid for elevai acquisition transaction costs | NaN | 0 | 0 | 150,000 |
| Purchases of property and equipment | NaN | 1 | 14,224 | NaN |
| Proceeds from issuance of loans | NaN | NaN | NaN | 0 |
| Net cash used in investing activities | NaN | -1 | 776 | -165,000 |
| Proceeds from issuance of common stock, net of costs | 190,001 | 0 | 86,314 | 3,397,476 |
| Proceeds from exercise of common stock warrants | NaN | 0 | 1,000,000 | NaN |
| Repayment of loans | 98,054 | 96,120 | 95,305 | 249,273 |
| Net cash provided by financing activities | 91,947 | -96,120 | 991,009 | 3,148,203 |
| Net (decrease) increase in cash and cash equivalents | -393,344 | -402,488 | -441,971 | 1,394,060 |
| Cash and cash equivalents - beginning of period | 706,740 | 1,109,228 | 157,139 | NaN |
| Cash and cash equivalents - end of period | 313,396 | 706,740 | 1,109,228 | NaN |